25周年を記念 1999-2024
*3年間で¥ 153396、たったの¥ 61358
フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
The Pair work together to Benefit Clothes Off Our Back(R) with Online Celebrity Shoe Auction KENILWORTH, N.J., April 15 /PRNewswire-FirstCall/...
Findings Suggest that Physical Effects are not the Only Way We Suffer - Allergies Impact Mood and Self-Perception KENILWORTH, N.J. and WHITEHOUSE...
The first prospective trial specifically designed to evaluate erectile function in ED patients with dyslipidemia CHICAGO, Dec. 10...
ORLANDO, Fla., Nov. 2 /PRNewswire-FirstCall/ -- Addressing more than 100 cardiologists and other medical experts from 24 countries, Fred Hassan...
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers will present 68 data presentations involving Schering-Plough's hepatitis...
LOS ANGELES, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. and the European Organisation for the Research and Treatment of Cancer...
Star of "Ugly Betty" and HomeAgain(R) Announce New Service that Gives Lost Pets a Second Chance at Life NEW YORK, Oct. 29 /PRNewswire-FirstCall/...
Findings from the ASSERT Trial Presented at EULAR BARCELONA, Spain, June 15 /PRNewswire-FirstCall/ -- Data presented today at the European...
CHICAGO, June 3 /PRNewswire/ -- Schering-Plough Corp. announced results from a Phase III study that showed maintenance chemotherapy with...
- EORTC 18991 Phase III Study Results Presented at ASCO - CHICAGO, June 2 /PRNewswire-FirstCall/ -- Long-term treatment with pegylated...
KENILWORTH, N.J., May 18 /PRNewswire-FirstCall/ -- A total of 20 oral and poster presentations on clinical studies with Schering-Plough's...
Global Trials of Nearly 30,000 Patients to Evaluate Unique and Distinct KENILWORTH, N.J., April 18 /PRNewswire-FirstCall/ -- Schering-Plough...
Schering-Plough Announces Presentation Of Phase II Trial Results For Novel Oral Thrombin Receptor Antagonist At The 2007 Annual Meeting Of The...
KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel...
The NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg* delivery device is the first nasal allergy spray acknowledged by the Arthritis...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約